SNPX

Synaptogenix, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website ynaptogen.com
Employees(FY) 5
ISIN US87167T3005

Performance

-11.64%

-18.14%

-25.74%

-44.19%

-61.0%

YTD

-59.2%

Profile

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

Advanced Technical Analysis

Technical Analysis of SNPX 2024-11-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward pressure, while the Oscillators Score of 53 suggests a neutral stance, and the Technical Score of 31 reinforces the bearish outlook. This combination implies that while there may be some oscillatory movements, the prevailing tre...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SNPX

Stock Rank

Recent News & Updates

2024-09-10 21:00
Synaptogenix Announces $5.0 Million Financing(Prnewswire)
2024-08-16 09:52
SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024(Investorplace)
2024-07-17 21:00
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury(Prnewswire)
2024-06-25 21:00
Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis(Prnewswire)
2024-05-19 23:54
SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024(Investorplace)
2024-05-06 21:00
Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery(Prnewswire)
2024-04-23 21:15
Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing(Prnewswire)
2024-04-08 21:15
Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics(Prnewswire)
2024-04-02 20:00
Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing(Prnewswire)
2023-12-18 20:00
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders(Prnewswire)
2023-12-05 20:00
Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's(Prnewswire)
2023-11-01 21:00
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology(Prnewswire)
2023-09-25 21:00
Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease(Yahoo Finance)
2023-09-06 21:00
Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study(Yahoo Finance)
2023-07-18 21:00
Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis(Yahoo Finance)
2023-07-12 21:00
Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience(Yahoo Finance)
2023-03-06 20:00
Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities(Yahoo Finance)
2022-12-15 20:00
Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease(Yahoo Finance)
2022-11-17 20:00
Synaptogenix Announces $15 Million Private Placement with Existing Investors(Yahoo Finance)
2022-10-18 21:00
Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022(Yahoo Finance)
2022-09-27 23:50
Synaptogenix Welcomes Lecanemab Phase 3 Trial Results(Yahoo Finance)
2022-08-11 21:00
Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network(Yahoo Finance)
2022-07-25 21:15
Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data(Yahoo Finance)
2022-07-20 21:15
Synaptogenix Announces Corporate Update Conference Call(Yahoo Finance)
2022-07-19 21:15
Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data(Yahoo Finance)
2022-05-16 21:15
Synaptogenix to Present at the Cell Symposium(Yahoo Finance)
2022-04-18 21:15
Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial(Yahoo Finance)
2022-04-04 21:15
New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease(Yahoo Finance)
2022-03-28 21:15
Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit(Yahoo Finance)
2022-03-21 21:15
Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum(Yahoo Finance)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.